# Ustekinumab

## Stelara inj 45mg/0.5mL

##### 臨採

| TAH Drug Code      | ISTE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|:-------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Plaque psoriasis: Treatment of moderate to severe plaque psoriasis in adults who are candidates for phototherapy or systemic therapy Psoriatic arthritis: Treatment of active psoriatic arthritis (as monotherapy or in combination with methotrexate) in adults.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Dosing             | Plaque psoriasis (Moderate to Severe) (100 kg or less) 45 mg subQ initially and 4 weeks later, followed by 45 mg every 12 weeks (Greater than 100 kg) 90 mg subQ initially and 4 weeks later, followed by 90 mg every 12 weeks Psoriatic arthritis 45 mg subQ initially and 4 weeks later, followed by 45 mg subQ every 12 weeks Coexistent moderate to severe plaque psoriasis and weight greater than 100 kg, 90 mg subQ initially and 4 weeks later, followed by 90 mg subQ every 12 weeks Crohn's disease & Ulcerative colitis (Moderate to Severe) (55 kg or less) Induction, 260 mg (two 130 mg/26 mL vials) IV over at least 1 hour as a single dose; maintenance, 90 mg subQ every 8 weeks beginning 8 weeks after induction dose (Greater than 55 kg to 85 kg) Induction, 390 mg (three 130 mg/26 mL vials) IV over at least 1 hour as a single dose; maintenance, 90 mg subQ every 8 weeks beginning 8 weeks after induction dose (Greater than 85 kg) Induction, 520 mg (four 130 mg/26 mL vials) IV over at least 1 hour as a single dose; maintenance, 90 mg subQ every 8 weeks beginning 8 weeks after induction dose |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Contraindications  | Hypersensitivity to ustekinumab or to any of the excipients of Stelara. Clinically important, active infection                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Adverse Effects    | Infection: Infection (27% to 70%; severe infection: ?3%) Central nervous system: Headache (5%), fatigue (3%), dizziness (2%), depression (1%) Dermatologic: Pruritus (2%) Gastrointestinal: Nausea (3%) Immunologic: Antibody development (3% to 6%) Local: Erythema at injection site (1% to 2%) Neuromuscular & skeletal: Arthralgia (3%), back pain (2%) Respiratory: Pharyngolaryngeal pain (2%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Pregnancy          | No Data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Lactation          | Contraindicated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

